Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Cananga odorata* leaf extract is a botanical extract derived from the leaves of the Ylang-Ylang tree. It contains bioactive flavonoids that have demonstrated inhibitory effects on the urokinase-type plasminogen activator (uPA), a serine protease critical for extracellular matrix degradation, tumor invasion, and metastasis. Elevated levels of uPA are consistently correlated with increased tumor aggressiveness and poorer clinical outcomes in breast cancer patients. Preclinical research, including studies on MCF-7 breast cancer cell lines, suggests that this extract may serve as a therapeutic agent by targeting the uPA pathway to reduce tumor cell migration and invasion. Extraction methods, such as ultrasound-assisted extraction, are often optimized to maximize the yield of these bioactive flavonoids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cananga odorata leaf extract.